Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4679589 | 0.83 | LMNA (0.38) | LMNASMN1; SMN2TDP1POLBNFE2L2 | |
| SCHEMBL30137376 | 0.83 | SMN1; SMN2 (0.42) | LMNASMN1; SMN2TDP1ALDH1A1POLB | |
| SCHEMBL1350726 | 0.83 | SMN1; SMN2 (0.42) | LMNASMN1; SMN2TDP1ALDH1A1POLB | |
| SCHEMBL13868027 | 0.79 | TDP1 (0.40) | LMNASMN1; SMN2TDP1ALDH1A1POLB | |
| SCHEMBL30046969 | 0.79 | SMN1; SMN2 (0.42) | LMNASMN1; SMN2TDP1ALDH1A1TSHR | |
| SCHEMBL4764441 | 0.79 | SMN1; SMN2 (0.42) | LMNASMN1; SMN2TDP1ALDH1A1TSHR | |
| SCHEMBL15204530 | 0.78 | PLCG1 (0.39) | LMNASMN1; SMN2TDP1POLBKDM4E | |
| SCHEMBL29388965 | 0.77 | RPS6KA5 (0.45) | LMNASMN1; SMN2KMT2ANFE2L2 | |
| SCHEMBL120643 | 0.77 | RPS6KA5 (0.45) | LMNASMN1; SMN2KMT2ANFE2L2 | |
| SCHEMBL29999657 | 0.77 | SMN1; SMN2 (0.50) | LMNASMN1; SMN2TDP1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| US-RE49582-E1 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-RE49582-E1 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230136177-A1 | IMMUNOMODULATING O-HET/ARYL AZALIDES | ZOETIS SERVICES LLC | 2023-05-04 | — | — | US | disclosed |
| US-20230129040-A1 | IMMUNOMODULATING AZALIDES | ZOETIS SERVICES LLC | 2023-04-27 | — | — | US | disclosed |
| US-20230129040-A1 | IMMUNOMODULATING AZALIDES | ZOETIS SERVICES LLC | 2023-04-27 | — | — | US | disclosed |
| US-11178870-B2 | Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients | MITSUI CHEMICALS AGRO, INC. (JP) | 2021-11-23 | — | — | US | disclosed |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-01-22 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-7456194-B2 | Imidazo-fused oxazolo [4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7429584-B2 | Furo[2.3-b]pyridine derivatives for the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-30 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| US-20070293501-A1 | Thioalkeneamides as Transketolase Inhibitors | ARRAY BIOPHARMA INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070099920-A1 | Benzimidazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-03 | — | — | US | disclosed |
| US-20070099920-A1 | Benzimidazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | LMNA 3446/4885SMN1; SMN2 1844/4885CA2 1125/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | LMNA 449/4885SMN1; SMN2 4859/4885CA2 4174/4885 |
| US-20230129040-A1 | IMMUNOMODULATING AZALIDES | IL2, MALT1, FCGRT | LMNA 4875/4885SMN1; SMN2 1802/4885CA2 3281/4885 |
| US-11178870-B2 | Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients | PNPO, CYP4X1, PDXK | LMNA 2672/4885SMN1; SMN2 3624/4885CA2 3320/4885 |
| US-20230136177-A1 | IMMUNOMODULATING O-HET/ARYL AZALIDES | IL2, MALT1, IL2RA | LMNA 4843/4885SMN1; SMN2 3190/4885CA2 4675/4885 |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | LMNA 1040/4885SMN1; SMN2 3770/4885CA2 4561/4885 |
| US-20070293501-A1 | Thioalkeneamides as Transketolase Inhibitors | TKT, AKR1A1, RRM2 | LMNA 3245/4885SMN1; SMN2 4647/4885CA2 2897/4885 |
| US-20070099920-A1 | Benzimidazoles useful as inhibitors of protein kinases | PDK1, AURKC, PIM3 | LMNA 2780/4885SMN1; SMN2 3387/4885CA2 3202/4885 |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5B, STAT5A, STAT3 | LMNA 3703/4885SMN1; SMN2 3600/4885CA2 4486/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | LMNA 3425/4885SMN1; SMN2 1476/4885CA2 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.